| Stereochemistry | ABSOLUTE |
| Molecular Formula | C24H21Cl2FN4O |
| Molecular Weight | 471.354 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C([C@H](N2N=CC=C2N1)C3=CC=C(Cl)C(Cl)=C3)C(=O)N4CCC[C@H]4C5=CC=C(F)C=C5
InChI
InChIKey=LADJRPDOKVCQCG-NZQKXSOJSA-N
InChI=1S/C24H21Cl2FN4O/c1-14-22(24(32)30-12-2-3-20(30)15-4-7-17(27)8-5-15)23(31-21(29-14)10-11-28-31)16-6-9-18(25)19(26)13-16/h4-11,13,20,23,29H,2-3,12H2,1H3/t20-,23+/m0/s1
| Molecular Formula | C24H21Cl2FN4O |
| Molecular Weight | 471.354 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Bristol-Myers Squibb developed BMS-394136, as a selective IKur inhibitor for the treatment of arrhythmias. IKur is a repolarizing K+ current encoded by the KCNA5 gene and is expressed predominantly in the atrium of human. IKur is a potential atrial-selective target for the treatment of atrial fibrillation. Atrial selectivity and safety of BMS-394136 were studied in phase I clinical trial in patients with heart diseases. However, further, development has been discontinued.
